Publications

Peer Reviewed Publications on Replicor's NAP Technology

Activity of nucleic acid polymers in rodent models of HBV infection.

Schöneweis K, Motter N, Roppert PL, Lu M, Wang B, Roehl I, Glebe D, Yang D, Morrey JD, Roggendorf M, Vaillant A. Antiviral Research 2017 epub Nov 8, 2017.

Read publication

Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial

Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, Schmid P, Le Gal F, Gordien E, Krawczyk A, Mijočević H, Karimzadeh H, Roggendorf M, Vaillant A. The Lancet Gastroenterology & Hepatology 2017 epub Sept 27, 2017.

Read publication

REP 301 study protocol

Read Publication

Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes

Guillot C, Martel N, Berby F, Bordes I, Hantz O, Blanchet M, Sureau C, Vaillant A, Chemin I. PLOS ONE 2017 12: e0179697.

Read Publication

Nucleic Acid Polymers with Accelerated Plasma and Tissue Clearance for Chronic Hepatitis B Therapy.

Roehl I, Seiffert S, Brikh C, Quinet Q, Jamard C, Dorfler N, Lockridge JA, Cova L, Andrew Vaillant A. Mol Ther Nuc Acids. 2017 8: 1-12.

Read Publication

Nucleic acid-based polymers effective against hepatitis B Virus infection in patients don’t harbor immunostimulatory properties in primary isolated liver cells.

Real CI, Werner M, Paul A, Gerken G, Schlaak JF, Vaillant A, Broering B, Sci. Reports. 2017 7: 43838.

Read Publication

Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection. Vaillant A. Antiviral Research 2016 133: 32-40.

Read Publication

Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection. Al-Mahtab M, Bazinet M, Vaillant A. PLOS ONE 2016 11: e0156667.

Read Publication

Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection. Noordeen F, Scougall CA, Grosse A, Qiao Q, Ajilian BB, Reache-Miller G, Finnie J, Werner M, Broering R, Schlaak J, Vaillant A, Jilbert AR.  PLOS ONE 10: e0140909.

Read Publication

Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo. Noordeen F, Vaillant A, Jilbert AR. Antimicrob Agents Chemother. 2013 57:5299-5306.

Read Publication

Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro. Noordeen F, Vaillant A, Jilbert AR. Antimicrob Agents Chemother. 2013 57:5291-5298.
Read Publication

Amphipathic DNA polymers exhibit antiviral activity against systemic murine Cytomegalovirus infection. Cardin RD, Bravo FJ, Sewell AP, Cummins J, Flamand L, Juteau JM, Bernstein DI, Vaillant A. Virology Journal 2009, 6:214.
Read Publication

Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Matsumura T, Hu Z, Kato T, Dreux M, Zhang YY, Imamura M, Hiraga N, Juteau JM, Cosset FL, Chayama K, Vaillant A, Liang TJ. Gastroenterology. 2009 Aug;137(2):673-81.
Read Publication

Amphipathic DNA polymers exhibit antiherpetic activity in vitro and in vivo. Bernstein DI, Goyette N, Cardin R, Kern ER, Boivin G, Ireland J, Juteau JM, Vaillant A. Antimicrob Agents Chemother. 2008 Aug;52(8):2727-33.
Read Publication

Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression. Guzman EM, Cheshenko N, Shende V, Keller MJ, Goyette N, Juteau JM, Boivin G, Vaillant A, Herold BC. Antivir Ther. 2007;12(8):1147-56. Erratum in: Antivir Ther. 2008;13(2):335.
Read Publication

Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers. Lee AM, Rojek JM, Gundersen A, Ströher U, Juteau JM, Vaillant A, Kunz S. Virology. 2008 Mar 1;372(1):107-17.
Read Publication

Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation. Vaillant A, Juteau JM, Lu H, Liu S, Lackman-Smith C, Ptak R, Jiang S. Antimicrob Agents Chemother. 2006 Apr;50(4):1393-401.
Read Publication